$HSCS
HeartSciences Inc.

2023 Q3 Form 10-K Financial Statement

#000095017023033424 Filed on July 19, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2023
Revenue $0.00 $0.00 $5.150K
YoY Change -100.0% -100.0% -64.16%
Cost Of Revenue $0.00 $0.00 $2.800K
YoY Change -100.0% -100.0% -64.51%
Gross Profit $0.00 $0.00 $2.350K
YoY Change -100.0% -100.0% -63.73%
Gross Profit Margin 45.63%
Selling, General & Admin $765.0K $1.064M $3.654M
YoY Change -23.27% 70.26% 113.17%
% of Gross Profit 155508.51%
Research & Development $565.6K $534.4K $2.461M
YoY Change 30.27% -60.58% -18.01%
% of Gross Profit 104717.87%
Depreciation & Amortization $7.338K $6.830K $26.92K
YoY Change 14.44% 5.08% 1.32%
% of Gross Profit 1145.53%
Operating Expenses $1.331M $1.599M $6.115M
YoY Change -7.03% -19.29% 29.67%
Operating Profit -$1.331M -$1.599M -$6.113M
YoY Change -6.95% -19.17% 29.8%
Interest Expense $36.26K -$33.96K -$243.2K
YoY Change -74.75% -55.91% -34.56%
% of Operating Profit
Other Income/Expense, Net -$36.20K $260.00 $1.850K
YoY Change -74.72% -84.8% -27.73%
Pretax Income -$1.370M -$1.632M -$6.354M
YoY Change -12.92% -20.49% 31.61%
Income Tax
% Of Pretax Income
Net Earnings -$1.367M -$1.632M -$6.354M
YoY Change -13.12% -20.49% 31.61%
Net Earnings / Revenue -123384.27%
Basic Earnings Per Share -$0.13 -$0.80
Diluted Earnings Per Share -$0.13 -$0.17 -$0.80
COMMON SHARES
Basic Shares Outstanding 10.36M 7.951M
Diluted Shares Outstanding 10.33M 7.951M

Balance Sheet

Concept 2023 Q3 2023 Q2 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $580.0K $1.660M $1.660M
YoY Change -86.42% 80.83% 80.83%
Cash & Equivalents $575.7K $1.660M $1.660M
Short-Term Investments
Other Short-Term Assets $40.37K $359.8K $359.8K
YoY Change 0.0% 7.02% 7.02%
Inventory $676.4K $676.4K $676.4K
Prepaid Expenses $453.0K $143.5K
Receivables $0.00 $0.00
Other Receivables $0.00 $0.00
Total Short-Term Assets $2.029M $2.697M $2.697M
YoY Change -62.68% 39.66% 39.66%
LONG-TERM ASSETS
Property, Plant & Equipment $59.00K $590.7K $590.7K
YoY Change -16.75% 272.49% 272.49%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $568.7K $590.7K $590.7K
YoY Change 334.83% 272.49% 272.49%
TOTAL ASSETS
Total Short-Term Assets $2.029M $2.697M $2.697M
Total Long-Term Assets $568.7K $590.7K $590.7K
Total Assets $2.598M $3.287M $3.287M
YoY Change -53.34% 57.33% 57.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $454.8K $631.4K $631.4K
YoY Change -0.2% -9.12% -9.12%
Accrued Expenses $631.0K $652.9K $652.9K
YoY Change 24.81% -42.96% -42.96%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $500.0K $500.0K $500.0K
YoY Change 284.62% -69.33% -69.33%
Total Short-Term Liabilities $1.898M $1.833M $1.833M
YoY Change 23.07% -47.19% -47.19%
LONG-TERM LIABILITIES
Long-Term Debt $500.0K $500.0K $500.0K
YoY Change -50.0% -88.74% -88.74%
Other Long-Term Liabilities $720.0K $723.8K $723.8K
YoY Change 421.85% 210.81% 210.81%
Total Long-Term Liabilities $1.220M $1.224M $1.224M
YoY Change 7.19% -73.82% -73.82%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.898M $1.833M $1.833M
Total Long-Term Liabilities $1.220M $1.224M $1.224M
Total Liabilities $3.118M $3.057M $3.057M
YoY Change 16.33% -62.47% -62.47%
SHAREHOLDERS EQUITY
Retained Earnings -$62.10M -$60.80M
YoY Change 10.89% 11.76%
Common Stock $10.67K $10.12K
YoY Change 30.56% 204.48%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$519.7K $230.6K $230.6K
YoY Change
Total Liabilities & Shareholders Equity $2.598M $3.287M $3.287M
YoY Change -53.34% 57.33% 57.33%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2023
OPERATING ACTIVITIES
Net Income -$1.367M -$1.632M -$6.354M
YoY Change -13.12% -20.49% 31.61%
Depreciation, Depletion And Amortization $7.338K $6.830K $26.92K
YoY Change 14.44% 5.08% 1.32%
Cash From Operating Activities -$1.404M -$1.862M -$5.774M
YoY Change -22.49% 56.14% 58.43%
INVESTING ACTIVITIES
Capital Expenditures $4.910K $7.590K $18.31K
YoY Change -32.25% -1048.7%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$4.910K -$7.590K -$18.31K
YoY Change -32.25% 848.7%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $1.720M $6.932M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 324.4K 1.599M 6.534M
YoY Change -93.73% 104.35% 70.12%
NET CHANGE
Cash From Operating Activities -1.404M -1.862M -5.774M
Cash From Investing Activities -4.910K -7.590K -18.31K
Cash From Financing Activities 324.4K 1.599M 6.534M
Net Change In Cash -1.085M -270.5K 742.2K
YoY Change -132.34% -34.02% 281.03%
FREE CASH FLOW
Cash From Operating Activities -$1.404M -$1.862M -$5.774M
Capital Expenditures $4.910K $7.590K $18.31K
Free Cash Flow -$1.409M -$1.869M -$5.792M
YoY Change -22.53% 56.78% 59.02%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--04-30
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001468492
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.0303
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-04-30
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-41422
CY2023 dei Entity Registrant Name
EntityRegistrantName
HEART TEST LABORATORIES, INC.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
TX
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-1344466
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
550 Reserve Street
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 360
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Southlake
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
76092
CY2023 dei City Area Code
CityAreaCode
682
CY2023 dei Local Phone Number
LocalPhoneNumber
237-7781
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Public Float
EntityPublicFloat
17900000
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10362284
CY2023 dei Auditor Firm
AuditorFirmId
200
CY2023 dei Auditor Name
AuditorName
HASKELL & WHITE LLP
CY2023 dei Auditor Location
AuditorLocation
Irvine, California
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1660467
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
918260
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2321
CY2023Q2 us-gaap Inventory Net
InventoryNet
676359
CY2022Q2 us-gaap Inventory Net
InventoryNet
674139
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
143460
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
49384
CY2023Q2 us-gaap Other Assets Current
OtherAssetsCurrent
40374
CY2022Q2 us-gaap Other Assets Current
OtherAssetsCurrent
40374
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
230557
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-6055796
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3287233
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2089448
CY2023Q2 us-gaap Deferred Offering Costs
DeferredOfferingCosts
175921
CY2022Q2 us-gaap Deferred Offering Costs
DeferredOfferingCosts
246400
CY2023Q2 us-gaap Assets Current
AssetsCurrent
2696581
CY2022Q2 us-gaap Assets Current
AssetsCurrent
1930878
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
61428
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
70035
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
529224
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
88535
CY2023Q2 us-gaap Assets
Assets
3287233
CY2022Q2 us-gaap Assets
Assets
2089448
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
631369
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
694745
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
623391
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1053636
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
29535
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
90968
CY2023Q2 us-gaap Notes Payable Current
NotesPayableCurrent
500000
CY2022Q2 us-gaap Notes Payable Current
NotesPayableCurrent
1630000
CY2023Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
48596
CY2022Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1220
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1832891
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3470569
CY2023Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
500000
CY2022Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
4441807
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
187450
CY2022Q2 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
232868
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
536335
CY2023Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1223785
CY2022Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
4674675
CY2023Q2 us-gaap Liabilities
Liabilities
3056676
CY2022Q2 us-gaap Liabilities
Liabilities
8145244
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
381
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
483
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10118440
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10118440
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3323942
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3323942
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
10118
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
3324
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
60977256
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
48343305
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-60757198
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-54402908
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5150
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14373
CY2023 us-gaap Cost Of Revenue
CostOfRevenue
2796
CY2022 us-gaap Cost Of Revenue
CostOfRevenue
7890
CY2023 us-gaap Gross Profit
GrossProfit
2354
CY2022 us-gaap Gross Profit
GrossProfit
6483
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2460868
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3001532
CY2023 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3654450
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1714350
CY2023 us-gaap Operating Expenses
OperatingExpenses
6115318
CY2022 us-gaap Operating Expenses
OperatingExpenses
4715882
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-6112964
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-4709399
CY2023 us-gaap Interest Expense
InterestExpense
243174
CY2022 us-gaap Interest Expense
InterestExpense
371619
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
250200
CY2023 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1848
CY2022 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
2558
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-241326
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-118861
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-6354290
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-4828260
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.80
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.80
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.45
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.45
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7950550
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7950550
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3318892
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3318892
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-1909589
CY2022 hscs Common Stock Issued To Non Emloyees
CommonStockIssuedToNonEmloyees
35000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
68396
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-4828260
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-6055796
CY2023 hscs Common Stock Issued Upon Exercise Of Pre Funded Warrants
CommonStockIssuedUponExerciseOfPreFundedWarrants
14
CY2023 hscs Common Stock Issued Upon Exercise Of Bridge Warrants
CommonStockIssuedUponExerciseOfBridgeWarrants
1141023
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
248308
CY2023 hscs Issuance Of Pre Funded Bridge Warrants
IssuanceOfPreFundedBridgeWarrants
150000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-6354290
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
230557
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-6354290
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-4828260
CY2023 us-gaap Depreciation
Depreciation
26915
CY2022 us-gaap Depreciation
Depreciation
26566
CY2023 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
61381
CY2022 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
156719
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
248308
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
68396
CY2022 hscs Stock Issued For Note Facility Fee
StockIssuedForNoteFacilityFee
35000
CY2023 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
171326
CY2022 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
22890
CY2023 hscs Gain On Settled Accounts Payable
GainOnSettledAccountsPayable
101200
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
250200
CY2023 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2321
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2321
CY2023 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2220
CY2022 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-76635
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-385773
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-72524
CY2023 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-60432
CY2022 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-246400
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
37824
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
358964
CY2023 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-310147
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
865343
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5773577
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3644144
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
18308
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1932
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-18308
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1932
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5194740
CY2023 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
17250
CY2023 hscs Issuance Of Common Stock For Exercise Of Pre Funded Warrants
IssuanceOfCommonStockForExerciseOfPreFundedWarrants
14
CY2023 hscs Issuance Of Common Stock For Bridge Warrant Exercises
IssuanceOfCommonStockForBridgeWarrantExercises
1141023
CY2023 hscs Issuance Of Common Stock Under Equity Line Net Of Offering Costs
IssuanceOfCommonStockUnderEquityLineNetOfOfferingCosts
429325
CY2023 hscs Issuance Of Pre Funded Warrants For Bridge Warrant Exercises
IssuanceOfPreFundedWarrantsForBridgeWarrantExercises
150000
CY2022 us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
500000
CY2022 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
4226000
CY2022 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
385145
CY2022 hscs Repayment Of Shareholder Note
RepaymentOfShareholderNote
-500000
CY2023 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
398260
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6534092
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3840855
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
742207
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
194779
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
918260
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
723481
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1660467
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
918260
CY2023 us-gaap Stock Issued1
StockIssued1
1500000
CY2023 hscs Issuance Of Common Stock For Bridge Note And Accrued Interest Conversions
IssuanceOfCommonStockForBridgeNoteAndAccruedInterestConversions
3618704
CY2023 hscs Issuance Of Common Stock For Series A And B Preferred Conversions
IssuanceOfCommonStockForSeriesAAndBPreferredConversions
703
CY2023 hscs Issuance Of Common Stock For Series C Preferred Conversions
IssuanceOfCommonStockForSeriesCPreferredConversions
348
CY2023 hscs Issuance Of Series C Preferred Stock For Note Conversion
IssuanceOfSeriesCPreferredStockForNoteConversion
130000
CY2023 hscs Issuance Of Common Stock For Cashless Bridge Warrant Exercises
IssuanceOfCommonStockForCashlessBridgeWarrantExercises
31
CY2023 hscs Issuance Of Common Stock Warrants In Payment Of Payables
IssuanceOfCommonStockWarrantsInPaymentOfPayables
171326
CY2022 hscs Issuance Of Common Stock Warrants In Connection With Bridge Financing
IssuanceOfCommonStockWarrantsInConnectionWithBridgeFinancing
555767
CY2023 hscs Warrants Issued As Underwriter Compensation
WarrantsIssuedAsUnderwriterCompensation
39953
CY2023 hscs Financed Insurance Premiums
FinancedInsurancePremiums
445636
CY2023 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
49227
CY2023 us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 1 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">– </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Organization and Operations</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Heart Test Laboratories, Inc. d/b/a HeartSciences (“HeartSciences” or the “Company”) is a medical technology company specializing in cardiovascular diagnostic technology. The Company is a Texas C-Corporation and is headquartered in Southlake, Texas.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HeartSciences’ initial focus is on applying novel technology to extend the clinical indications for use of an electrocardiograph (“ECG”) device. Its first device, the MyoVista is an ECG that is being developed for use in a wide range of clinical settings and is designed to provide diagnostic information to a qualified healthcare professional on cardiac dysfunction which has traditionally only been provided using cardiac imaging. In addition, the MyoVista provides conventional ECG information. The Company plans to market its device both domestically and internationally to various hospitals, clinics, and medical centers and manufacture the devices using outsourced production facilities. To date the Company has had small amounts of revenue from key opinion leader engagement and establishment of distributor relationships outside the United States during the development and product improvement phase of the MyoVista. The Company is preparing to seek U.S. Food and Drug Administration (“FDA”) clearance of the MyoVista during 2023.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On June 3, 2022, the Company filed a Certificate of Amendment to the Amended and Restated Certificate of Formation with the Secretary of the State of Texas to effect a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1-for-</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_062e5f49-907b-47f4-9b05-ef0c26cb9bcb;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> reverse stock</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> split of its outstanding shares of common stock, with an effective date of June 10, 2022. As a result of the reverse stock split, every </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company's issued and outstanding pre-reverse split common stock were combined into one share of common stock, except to the extent that the reverse stock split resulted in any of the Company's shareholders owning a fractional share, which was rounded up to the next highest whole share if such fraction was equal to or greater than one-half. In connection with the reverse stock split, there was no change in the par value per share of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. All share and per share numbers have been retroactively adjusted to give effect to the reverse stock split for all periods presented, unless otherwise indicated.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2023 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-33 reverse stock
CY2022Q2 hscs Pre Reverse Split Common Stock Issued
PreReverseSplitCommonStockIssued
33
CY2022Q2 hscs Pre Reverse Split Common Stock Outstanding
PreReverseSplitCommonStockOutstanding
33
CY2022Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
28662
CY2023Q2 hscs Inventory Reserve For Obsolescence
InventoryReserveForObsolescence
44476
CY2022Q2 hscs Inventory Reserve For Obsolescence
InventoryReserveForObsolescence
81446
CY2023Q2 us-gaap Inventory Net
InventoryNet
676359
CY2022Q2 us-gaap Inventory Net
InventoryNet
674139
CY2023 hscs Useable Life Of Device
UseableLifeOfDevice
P7Y
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-60800000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-54400000
CY2022Q2 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
5200000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities as of the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</span></p>
CY2023Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
322996
CY2022Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
359965
CY2023Q2 hscs Inventory Sub Assemblies
InventorySubAssemblies
347436
CY2022Q2 hscs Inventory Sub Assemblies
InventorySubAssemblies
345217
CY2023Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
21741
CY2022Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
21741
CY2023Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
28662
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
533295
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
514987
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
471867
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
444952
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
61428
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
70035
CY2023 us-gaap Depreciation
Depreciation
26915
CY2022 us-gaap Depreciation
Depreciation
26566
CY2023Q2 us-gaap Deferred Offering Costs
DeferredOfferingCosts
175921
CY2022Q2 us-gaap Deferred Offering Costs
DeferredOfferingCosts
246400
CY2023Q2 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
CY2022Q2 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
CY2023Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
0
CY2022Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
0
CY2023Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
0
CY2022Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
0
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Concentration of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments which potentially subject the Company to concentrations of credit risk consist primarily of cash. The Company maintains its cash with high-credit quality financial institutions. At April 30, 2023 and April 30, 2022, the Company had cash balances in excess of federally insured limits of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. The Company does not anticipate non-performance by its financial institution.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2023Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
1400000
CY2022Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
700000
CY2023Q2 us-gaap Notes Payable
NotesPayable
1000000
CY2022Q2 us-gaap Notes Payable
NotesPayable
6071807
CY2023Q2 us-gaap Notes Payable Current
NotesPayableCurrent
500000
CY2022Q2 us-gaap Notes Payable Current
NotesPayableCurrent
1630000
CY2023Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
500000
CY2022Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
4441807
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10118440
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3323942
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3323942
CY2023 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
6794498
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10118440
CY2023 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2022 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2022Q2 hscs Warrants Outstanding And Exercisable
WarrantsOutstandingAndExercisable
1442401
CY2022Q2 hscs Class Of Warrant Or Right Weighted Average Strike Price Per Share
ClassOfWarrantOrRightWeightedAverageStrikePricePerShare
9.00
CY2023 hscs Warrants Outstanding And Exercisable Issued
WarrantsOutstandingAndExercisableIssued
4052826
CY2023 hscs Class Of Warrant Or Right Weighted Average Strike Price Per Share Issued
ClassOfWarrantOrRightWeightedAverageStrikePricePerShareIssued
3.75
CY2023 hscs Warrants Outstanding And Exercisable Exercised
WarrantsOutstandingAndExercisableExercised
1524159
CY2023 hscs Class Of Warrant Or Right Weighted Average Strike Price Per Share Exercised
ClassOfWarrantOrRightWeightedAverageStrikePricePerShareExercised
3.86
CY2023 hscs Warrants Outstanding And Exercisable Forfeited
WarrantsOutstandingAndExercisableForfeited
-14766
CY2023 hscs Class Of Warrant Or Right Weighted Average Strike Price Per Share Forfeited
ClassOfWarrantOrRightWeightedAverageStrikePricePerShareForfeited
13.96
CY2023 hscs Warrants Outstanding And Exercisable Cancelled
WarrantsOutstandingAndExercisableCancelled
1365960
CY2023 hscs Exercise Price Per Share Cancelled
ExercisePricePerShareCancelled
5.16
CY2023 hscs Class Of Warrant Or Right Weighted Average Strike Price Per Share Cancelled
ClassOfWarrantOrRightWeightedAverageStrikePricePerShareCancelled
5.16
CY2023Q2 hscs Warrants Outstanding And Exercisable
WarrantsOutstandingAndExercisable
2590342
CY2023Q2 hscs Class Of Warrant Or Right Weighted Average Strike Price Per Share
ClassOfWarrantOrRightWeightedAverageStrikePricePerShare
3.73
CY2023Q2 hscs Class Of Warrant Or Right Number Of Securities Cancelled By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCancelledByWarrantsOrRights
1365960
CY2023 hscs Share Based Compensation Arrangement By Share Based Payment Award Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTerm
P10Y
CY2023Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
9701650
CY2022Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
8387881
CY2023Q2 hscs Deferred Tax Assets Start Up Costs
DeferredTaxAssetsStartUpCosts
934999
CY2022Q2 hscs Deferred Tax Assets Start Up Costs
DeferredTaxAssetsStartUpCosts
1036080
CY2023Q2 hscs Deferred Tax Assets Stock Option And Warrant Payments
DeferredTaxAssetsStockOptionAndWarrantPayments
538669
CY2022Q2 hscs Deferred Tax Assets Stock Option And Warrant Payments
DeferredTaxAssetsStockOptionAndWarrantPayments
423624
CY2023Q2 hscs Deferred Tax Liabilities Accumulated Depreciation
DeferredTaxLiabilitiesAccumulatedDepreciation
3111
CY2022Q2 hscs Deferred Tax Liabilities Accumulated Depreciation
DeferredTaxLiabilitiesAccumulatedDepreciation
2668
CY2023Q2 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
255600
CY2022Q2 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
255600
CY2023Q2 hscs Deferred Tax Assets Research And Development Warrants
DeferredTaxAssetsResearchAndDevelopmentWarrants
21488
CY2022Q2 hscs Deferred Tax Assets Research And Development Warrants
DeferredTaxAssetsResearchAndDevelopmentWarrants
21488
CY2023Q2 hscs Deferred Tax Assets Liabilities Net Before Valuation Allowance
DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance
11449295
CY2022Q2 hscs Deferred Tax Assets Liabilities Net Before Valuation Allowance
DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance
10122005
CY2023Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
11449295
CY2022Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
10122005
CY2022Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2023Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2023 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
On September 27, 2022, the Company entered into the First Amendment to Lease (the “Lease Amendment”), which amended the Lease Agreement to document the exercise of its option to extend the term of the lease for an additional 64 months, commencing February 1, 2023, and expiring on May 31, 2028 (the “Extension Term”). Pursuant to the amendment, the Company will pay initial monthly payments of $13,129, beginning February 2023, subject to 3% annual increases. The Company will receive a four-month rent concession at the start of the lease extension period on February 1, 2023. The lease also provides for allowances for tenant improvements which may be credited to rent within the first twelve-months of the Extension Term. As a result of this amendment, the Company recognized an additional right-of-use asset and corresponding lease liability of $549,227. The right-of-use asset and liability recognized equals the present value of the remaining payments due under the amended lease.
CY2023 hscs Operating Lease Option To Extend Additional Lease Term
OperatingLeaseOptionToExtendAdditionalLeaseTerm
P64M
CY2023 hscs Operating Lease Commencing Date
OperatingLeaseCommencingDate
2023-02-01
CY2023 hscs Operating Lease Expiring Date
OperatingLeaseExpiringDate
2028-05-31
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
13129
CY2023 hscs Operating Lease Percentage Of Annual Increase
OperatingLeasePercentageOfAnnualIncrease
0.03
CY2023Q2 hscs Operating Lease Increase Of Lease Liabilities
OperatingLeaseIncreaseOfLeaseLiabilities
549227
CY2023Q2 hscs Operating Lease Increase Of Right Of Use Assets
OperatingLeaseIncreaseOfRightOfUseAssets
549227
CY2023 hscs Operating Leases Rent Expense
OperatingLeasesRentExpense
167309
CY2022 hscs Operating Leases Rent Expense
OperatingLeasesRentExpense
179364
CY2023Q2 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.12
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
529224
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
29535
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
536335
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
565870
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y1M6D
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.12
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
98053
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
161164
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
165190
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
169307
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
173559
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
14494
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
781767
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
215897
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
565870

Files In Submission

Name View Source Status
0000950170-23-033424-index-headers.html Edgar Link pending
0000950170-23-033424-index.html Edgar Link pending
0000950170-23-033424.txt Edgar Link pending
0000950170-23-033424-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
hscs-20230430.htm Edgar Link pending
hscs-20230430.xsd Edgar Link pending
hscs-ex10_29.htm Edgar Link pending
hscs-ex21_1.htm Edgar Link pending
hscs-ex31_1.htm Edgar Link pending
hscs-ex31_2.htm Edgar Link pending
hscs-ex32_1.htm Edgar Link pending
hscs-ex32_2.htm Edgar Link pending
hscs-ex4_14.htm Edgar Link pending
img148626354_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
hscs-20230430_cal.xml Edgar Link unprocessable
hscs-20230430_def.xml Edgar Link unprocessable
hscs-20230430_lab.xml Edgar Link unprocessable
hscs-20230430_pre.xml Edgar Link unprocessable
hscs-20230430_htm.xml Edgar Link completed
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable